Quality of Life Assessment of Aortic Valve Neocuspidization | 93440

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Quality of Life Assessment of Aortic Valve Neocuspidization for Autologous Pericardium: A Systematic Review

Author(s): Komarov RN, Badalyan SS*, Lenkovets M, Tcheglov MI, Magomedova KA and IM Sechenov


In 2007, Ozaki et al. conducted the first aortic valve neocuspidation utilizing glutaraldehyde-treated autologous pericardium. Because long-term anticoagulation is not necessary, this procedure has become an option to tissue and mechanical valves. This approach has proven to be a viable alternative to bio prosthetic and mechanical valves, both of which have obvious drawbacks. Digital databases were searched from 2014 to 2022 for the phrases “autologous pericardium”, “aortic valve replacement”, and “aortic valve reconstruction”. Mortality, freedom from surgery, thromboembolic and endocarditis events, and echocardiography findings were all analysed in this study. Non-cardiac causes of death and reoperation were virtually nonexistent. Very few cases of thromboembolic or endocarditis have been reported in this study. A reduced average peak pressure gradient was seen in all investigations following surgery. Autologous pericardium-based aortic valve replacement is both safe and effective. Neocuspidization of the aortic valve offers a less invasive surgical option to biological and mechanical prostheses. Without the requirement for long-term oral anticoagulation, the short- and midterm outcomes are equivalent. Long-term follow-up data is necessary for this new strategy to be broadly implemented.

Share this article